Generic Actoplus Met XR

The first patent for Actoplus Met XR (pioglitazone and metformin XR) expired in January 2011; however, no generic versions have been produced yet, probably because other patents are preventing this. Although you may find so-called "generic Actoplus Met XR" on the Internet, you have no way of knowing if the product is genuine. It is best to wait until an approved generic version is available.

Can I Buy Generic Actoplus Met XR?

Actoplus Met® XR (pioglitazone and metformin XR) is a prescription medication that has been licensed to treat type 2 diabetes. It is a combination of two different diabetes drugs: pioglitazone hydrochloride (Actos®) and extended-release metformin hydrochloride. It is a long-acting product that is taken just once a day in the evening.
 
Actoplus Met XR is manufactured by Takeda Pharmaceuticals. It is currently under the protection of a patent that prevents any generic Actoplus Met XR from being manufactured in the United States. Yet, if you search the Internet for "generic Actoplus Met XR," you may find a number of companies selling it. These medicines may be fake, substandard, and potentially dangerous.
 
Generic Actoplus Met XR may be available from another country, but there is really no way of knowing if you are getting genuine Actoplus Met XR or not. You should not buy any so-called generic versions until an approved product is available in the United States.
 

When Will Generic Actoplus Met XR Be Available?

The first listed patent for Actoplus Met XR expired in January 2011. However, there is good reason to believe that other patents (which expire later) will provide protection against generic competition for this medication.
 
A generic version of Actoplus Met (which contains immediate-release metformin, instead of extended-release metformin) will not be available until December 14, 2012. It is unlikely that this extended-release version (which was approved after the immediate-release version) would "go generic" first.
 
Generic Actoplus Met XR Article Continues on Next Page >
Other Articles in This eMedTV Presentation